Neonatal BCG Vaccination Decreases Eczema Incidence at 5 years: The MIS BAIR Randomised Controlled Trial.
journal contribution
posted on 2025-09-10, 04:39 authored by Laure PittetLaure Pittet, Nicole MessinaNicole Messina, Kate FrancisKate Francis, Susan DonathSusan Donath, Katie L Flanagan, Emily K Forbes, Kaya GardinerKaya Gardiner, Roderic PhillipsRoderic Phillips, Anne-Louise PonsonbyAnne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Michael SouthMichael South, Peter VuillerminPeter Vuillermin, Dan Casalaz, Richard CurtisRichard Curtis, On the behalf of the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) GroupNo description supplied
Funding
Extending the MIS BAIR randomised trial of BCG to prevent childhood allergy and infection : National Health and Medical Research Council | 1099676
BCG immunisation to prevent allergy in children: an intervention trial : National Health and Medical Research Council | 1051228
Improving the diagnosis, treatment and prevention of infectious diseases in children : National Health and Medical Research Council | 1197117
History
Related Materials
- 1.
- 2.
- 3.
- 4.
- 5.
Publisher
WileyJournal
AllergyLanguage
engLocation
DenmarkMedium
Print-ElectronicNumber
all.16677Publisher DOI
Publisher licence
CC BYOnline publication date
2025-07-31Publication date
2025-07-31Associated identifiers
grant.7874755 (dimensions-grant-id)Publication status
- Published online
Usage metrics
Categories
Keywords
atopic dermatitispreventionvaccines3213 Paediatrics32 Biomedical and Clinical SciencesTuberculosisTuberculosis VaccineImmunizationOrphan DrugEmerging Infectious DiseasesPreventionPediatricInfectious DiseasesVaccine RelatedRare Diseases3.4 Vaccines3 Good Health and Well BeingOn the behalf of the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) GroupAllergy3204 Immunology
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC